Business & Markets
CSL pays $355 million upfront in Alentis drug partnership
Alentis may also receive up to $1.2 billion in commercial milestones, while development funding sits outside that ceiling. The drug remains experimental, with its lead program still in Phase 2.
Executive summary
- The cash terms: CSL will pay Alentis Therapeutics US$355 million upfront, and Alentis can earn up to US$1.2 billion in commercial milestone payments under an exclusive agreement to jointly develop and promote lixudebart. CSL will also fund ongoing and planned trials; the companies did not quantify those development costs in the milestone ceiling.[1][2]
- An early-stage program: Lixudebart is an investigational antibody being tested in a Phase 2 trial for ANCA-associated vasculitis with rapidly progressive glomerulonephritis. ClinicalTrials.gov lists the controlled study as recruiting and has no results posted, so the deal does not establish that the drug works or will reach the market.[3][1]
- More indications are planned: The companies also plan Phase 2 development in focal segmental glomerulosclerosis and primary sclerosing cholangitis. If a product is commercialized, they will share global profits 55% to CSL and 45% to Alentis, according to the agreement announcement.[1][2]
CSL and Switzerland-based Alentis Therapeutics have agreed to jointly develop and co-promote lixudebart, an investigational antibody aimed at rare kidney and liver diseases. CSL will pay US$355 million upfront, Alentis may receive up to US$1.2 billion in commercial milestone payments, and the companies will split any global profits after commercialization 55% to CSL and 45% to Alentis.[1][2]
The milestone ceiling is not the whole potential cost to CSL. The company will also fund the ongoing Phase 2 RENAL trial, a planned Phase 3 trial for ANCA-associated vasculitis with rapidly progressive glomerulonephritis, and planned Phase 2 trials in two additional conditions. The companies' public announcement did not put a value on that development funding.[1][2]
Lixudebart, previously known as ALE.F02, is in a randomized, placebo-controlled Phase 2 study for ANCA-associated vasculitis with rapidly progressive glomerulonephritis, a severe autoimmune kidney disease. ClinicalTrials.gov lists the trial as recruiting, with estimated completion in 2027, and says no results have been posted to the registry.[3]
The companies' announcement cites an interim analysis involving 26 patients and reports preliminary improvement in kidney-function measures. It does not provide comparative effect sizes in the deal notice, while the registry has no posted trial results. That company-reported signal is not evidence of regulatory approval or proof that lixudebart benefits patients; the treatment remains investigational.[1][3]
CSL and Alentis said they plan to study lixudebart in focal segmental glomerulosclerosis, a progressive kidney disorder, and primary sclerosing cholangitis, a chronic liver disease. Both are planned Phase 2 programs rather than established treatments. The partners say the antibody targets claudin-1 and is intended to address inflammatory and fibrotic signaling, but the proposed mechanism and its clinical value remain to be tested in larger studies.[1][3][4]
The deal gives CSL a broad role in development and commercialization while keeping Alentis involved in co-development and promotion. Its maximum milestone figure depends on future commercial events, and any eventual revenue depends on successful trials, regulatory review and market launch.[1][2]